Evidence map›Paper›PMID 39035539›Full record

ArticleHeliyon2024

Image analysis Uncovers associations between immune landscape, collagen structure, and neoadjuvant chemotherapy in high-grade serous ovarian carcinomas.

Arpit Aggarwal, Germán Corredor, Pingfu Fu, Tilak Pathak, Tuomas Mirtti, Susan Modesitt, T Rinda Soong, Anant Madabhushi

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arpit AggarwalGeorgia Tech, Department of Biomedical Engineering, Atlanta, GA, USA.
Germán CorredorEmory University, Department of Biomedical Engineering, Atlanta, GA, USA.
Pingfu FuCase Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, OH, USA.
Tilak PathakEmory University, Department of Biomedical Engineering, Atlanta, GA, USA.
Tuomas MirttiDepartment of Pathology, Helsinki University Hospital, Helsinki, Finland.
Susan ModesittGynecology and Obstetrics Department, Emory University School of Medicine, Atlanta, GA, USA.
T Rinda SoongDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh PA, USA.
Anant MadabhushiGeorgia Tech, Department of Biomedical Engineering, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The changes in the tumor microenvironment of high-grade serous ovarian carcinomas following neoadjuvant chemotherapy are a complex area of study. Previous research underscores the importance of investigating the immune and collagen components within the tumor microenvironment for prognostic implications. Methods: In this study, we utilized computational pathology techniques with Hematoxylin and Eosin-stained images to quantitatively characterize the immune and collagen architecture within the tumor microenvironment of patients with high-grade serous ovarian carcinoma. Results: Our analysis of 12 pre- and post-neoadjuvant chemotherapy images revealed an increase in immune infiltrate, primarily within the epithelial region. Additionally, post-neoadjuvant chemotherapy images exhibited chaotic collagen architecture compared to pre-neoadjuvant chemotherapy images. Importantly, features extracted from post-neoadjuvant chemotherapy images showed associations with overall survival, potentially aiding in the selection of patients for immunotherapy trials. Conclusions: These findings offer critical insights into the changes in the tumor microenvironment of high-grade serous ovarian carcinomas following neoadjuvant chemotherapy and their potential implications for clinical outcomes.

Identifiers

PMID39035539
PMCPMC11259872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.